CSL share price falls as it reveals blockbuster new product pipeline

Is the CSL Limited (ASX:CSL) share price cheap?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price may be down today, but the future looks good after it revealed a huge pipeline of new products it's working on commercialising over the next three years or more.

In a 116 page presentation to investors this morning the company boasted of some recent clinical successes and a new product pipeline that could generate big profits for investors in the years to come.

So let's take a look at some of the key products it has in the works and when they might be commercialised:

  • CSL 112 – is a therapy to help heart attack vitamins with potential commercialisation from 2022, more on this below (Categorised as a potential 'breakthrough' medicine by CSL)
  • CSL 312 – a "monoclonal antibody" at Phase II stage in development "for use in multiple indications including as a subcutaneous therapy for HAE" (hereditary angioedema) (Categorised as a potential 'breakthrough' medicine by CSL)
  • CSL 346 – "A humanised mAb that antagonises VEGF-B and is administered via subcutaneous injection either as a standalone therapy or in combination with other agents for the potential treatment of diabetic nephropathy, or other conditions associated with aberrant lipid metabolism". (Categorised as a potential 'breakthrough' medicine by CSL)
  • CSL 730 – a "novel recombinant human Fc multimer for treatment of patients with immune complex-mediated autoimmune diseases. Developed in collaboration with Momenta Pharmaceuticals."
  • CSL 346 – "A humanised mAb that antagonises VEGF-B and is administered via subcutaneous injection either as a standalone therapy or in combination with other agents for the potential treatment of diabetic nephropathy, or other conditions associated with aberrant lipid metabolism."

According to its website and today's presentation CSL currently has a total of 30 different products at the pre-clinical, clinical trial,  or product registration / launch stage, with $702 million invested in research and development over 2017-2018.

Its CSL 112 trial to help prevent secondary heart attacks in patients is recruiting more than 17,000 patients and it's investing more than US$500 million in total on the CSL 112 trials, with the interim efficacy result of the trial expected in April 2021.

If the trial meets its clinical endpoints then CSL hopes to have the treatment commercialised by 2022.

Source: CSL investor presentation, December 5, 2018

What the financial benefits of CSL 112 may be is unclear, but according to management it's a potentially transformational therapy with huge potential. Then again the trial may flop, so investors should be cautious.

In other positive news for investors today CSL also reported one of its cell-based flu vaccines sold under its Sequiris division showed better rates of immunisation for patients compared to more traditional egg-based flu vaccines.

CSL looks a good long-term bet for investors and the share price is well off recent highs.

Motley Fool contributor Yulia Mosaleva owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

Why Domino's, Lynas, Paladin Energy, and St Barbara shares are sinking today

These shares are having a tough session. What's going on?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Amcor, Boss Energy, Brickworks, and Mineral Resources shares are tumbling today

These shares are starting the week in the red. But why?

Read more »

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

The worst 3 ASX 200 stocks to buy and hold in October unmasked

You would have done well to avoid these three ASX 200 stocks in October.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why AFT, Amcor, Corporate Travel, and Macquarie shares are falling today

These shares are ending the week in the red. But why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why AGL, Imugene, Star, and Woolworths shares are dropping today

These shares are dropping on Thursday. Let's see why investors are selling them.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Fallers

Why Corporate Travel Management, JB Hi-Fi, Mineral Resources, and Syrah shares are rising

These shares are having a strong session. Why are investors buying their shares?

Read more »

A guys points his fingers down.
Share Fallers

Why Brainchip, Cettire, Star, and Woolworths shares are being sold off today

These shares are having a difficult time on hump day. But why?

Read more »

Three guys in shirts and ties give the thumbs down.
Share Fallers

Why Black Cat, BlueScope, Cettire, and Coronado shares are falling today

These shares are missing out on the good times on Tuesday. But why?

Read more »